clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Eickel V et al. Emergence of respiratory Streptococcus agalactiae isolates in cystic fibrosis patients. 2009 PLoS ONE pmid:19247473
Yonezawa H et al. Impact of Helicobacter pylori biofilm formation on clarithromycin susceptibility and generation of resistance mutations. 2013 PLoS ONE pmid:24039906
Jakobsson HE et al. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. 2010 PLoS ONE pmid:20352091
Juste RA et al. On the prevalence of M. avium subspecies paratuberculosis DNA in the blood of healthy individuals and patients with inflammatory bowel disease. 2008 PLoS ONE pmid:18596984
Kim BJ et al. Discovery of a novel hsp65 genotype within Mycobacterium massiliense associated with the rough colony morphology. 2012 PLoS ONE pmid:22693637
Shin SH et al. Helicobacter pylori Eradication Prevents Metachronous Gastric Neoplasms after Endoscopic Resection of Gastric Dysplasia. 2015 PLoS ONE pmid:26580072
Desai S et al. The Epidemiology of Invasive Haemophilus influenzae Non-Serotype B Disease in Ontario, Canada from 2004 to 2013. 2015 PLoS ONE pmid:26569613
Rubio M et al. Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Complex. 2015 PLoS ONE pmid:26448181
Makobongo MO et al. In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori. 2013 PLoS ONE pmid:23935905
Chauffour A et al. Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice. 2016 PLoS Negl Trop Dis pmid:27755552
Converse PJ et al. Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease. 2015 PLoS Negl Trop Dis pmid:26042792
Friedman ND et al. Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort. 2013 PLoS Negl Trop Dis pmid:23875050
Cowan R et al. Mycobacterium ulcerans treatment--can antibiotic duration be reduced in selected patients? 2015 PLoS Negl Trop Dis pmid:25658304
Gopinath K and Singh S Non-tuberculous mycobacteria in TB-endemic countries: are we neglecting the danger? 2010 PLoS Negl Trop Dis pmid:20436962
Vinh H et al. A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children. 2011 PLoS Negl Trop Dis pmid:21829747
Almeida D et al. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice. 2011 PLoS Negl Trop Dis pmid:21245920
Hobbie SN et al. Genetic reconstruction of protozoan rRNA decoding sites provides a rationale for paromomycin activity against Leishmania and Trypanosoma. 2011 PLoS Negl Trop Dis pmid:21629725
Trunck LA et al. Molecular basis of rare aminoglycoside susceptibility and pathogenesis of Burkholderia pseudomallei clinical isolates from Thailand. 2009 PLoS Negl Trop Dis pmid:19771149
Gordon CL et al. All-oral antibiotic treatment for buruli ulcer: a report of four patients. 2010 PLoS Negl Trop Dis pmid:21152060
O'Brien DP et al. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study. 2012 PLoS Negl Trop Dis pmid:22272368
Connolly LE et al. Why is long-term therapy required to cure tuberculosis? 2007 PLoS Med. pmid:17388672
Corrales-Medina VF et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. 2011 PLoS Med. pmid:21738449
Skalet AH et al. Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial. 2010 PLoS Med. pmid:21179434
Letek M et al. The genome of a pathogenic rhodococcus: cooptive virulence underpinned by key gene acquisitions. 2010 PLoS Genet. pmid:20941392
Balcan D et al. Modeling the critical care demand and antibiotics resources needed during the Fall 2009 wave of influenza A(H1N1) pandemic. 2009 PLoS Curr pmid:20029670
Fouts DE et al. Major structural differences and novel potential virulence mechanisms from the genomes of multiple campylobacter species. 2005 PLoS Biol. pmid:15660156
Matsukawa Y et al. Long term changes in platelet counts after H. pylori eradication in non-ITP patients. 2010 Platelets pmid:20849211
Matsukawa Y et al. Helicobacter pylori eradication reduces platelet count in patients without idiopathic thrombocytopenic purpura. 2007 Platelets pmid:17365854
Lee D et al. Localized Mycobacterium avium-intracellulare mastitis in an immunocompetent woman with silicone breast implants. 1995 Plast. Reconstr. Surg. pmid:7809228
Hess CL et al. Mycobacterium marinum infections of the upper extremity. 2005 Plast. Reconstr. Surg. pmid:15731663
Dantas da Silva LL et al. Antibacterial activity of a stearic acid derivative from Stemodia foliosa. 2002 Planta Med. pmid:12494347
Kwak HM et al. The efficacy of cefazolin plus macrolide (erythromycin or clarithromycin) versus cefazolin alone in neonatal morbidity and placental inflammation for women with preterm premature rupture of membranes. 2013 Placenta pmid:23465535
MAC management. 1996 PI Perspect pmid:11363967
Cheng B Preventing opportunistic infections. 1995 PI Perspect pmid:11362422
Liu WH et al. In vitro anti-Helicobacter pylori activity of diallyl sulphides and protocatechuic acid. 2008 Phytother Res pmid:17705145
Nostro A et al. Effects of combining extracts (from propolis or Zingiber officinale) with clarithromycin on Helicobacter pylori. 2006 Phytother Res pmid:16521108
Lawal TO et al. Combination studies of Eucalyptus torelliana F. Muell. leaf extracts and clarithromycin on Helicobacter pylori. 2012 Phytother Res pmid:22318891
Safak B et al. In vitro anti-Helicobacter pylori activity of usnic acid. 2009 Phytother Res pmid:19367654
Stege PW et al. Antimicrobial activity of aqueous extracts of Larrea divaricata Cav (jarilla) against Helicobacter pylori. 2006 Phytomedicine pmid:17085295
Dabos KJ et al. The effect of mastic gum on Helicobacter pylori: a randomized pilot study. 2010 Phytomedicine pmid:19879118
Celik H and Ayar A Clarithromycin inhibits myometrial contractions in isolated human myometrium independent of stimulus. 2002 Physiol Res pmid:12234115
Kim PK and Dorshimer GW Case report: peptic ulcer disease in a professional athlete. 2009 Phys Sportsmed pmid:20048520
Guo D et al. The cardiotoxicity of macrolides: a systematic review. 2010 Pharmazie pmid:21038838
Valizadeh H et al. Antibacterial activity of clarithromycin loaded PLGA nanoparticles. 2012 Pharmazie pmid:22393833
Togami K et al. Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells. 2012 Pharmazie pmid:22764569
Hamdan II Comparative in vitro investigations of the interaction between some macrolides and Cu(II), Zn(II) and Fe(II). 2003 Pharmazie pmid:12685822
Lohitnavy M et al. Pharmacokinetic and bloequivalence studies of generic clarithromycin tablets in healthy male volunteers. 2003 Pharmazie pmid:12622260
Chadha R et al. Quantitative analysis of in vitro compatibility of binary and ternary mixtures of nitroimidazole and macrolides in combination with omeprazole using a calorimetric technique. 2007 Pharmazie pmid:17557738
Najib MM et al. Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia. 2000 Pharmacotherapy pmid:10772376
Mertl SL The role of clarithromycin in the prophylaxis of disseminated Mycobacterium avium-intracellulare infection in patients with AIDS. 1996 May-Jun Pharmacotherapy pmid:8726597
Mor N et al. Accumulation of clarithromycin in macrophages infected with Mycobacterium avium. 1994 Jan-Feb Pharmacotherapy pmid:8159593
Auclair B et al. Potential interaction between itraconazole and clarithromycin. 1999 Pharmacotherapy pmid:10600094
Khamaisi M and Leitersdorf E Severe hypoglycemia from clarithromycin-repaglinide drug interaction. 2008 Pharmacotherapy pmid:18447665
Otsuka SH Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction. 2013 Pharmacotherapy pmid:23471710
Nicholson SC et al. Antimicrobial-associated acute hepatitis. 2002 Pharmacotherapy pmid:12066973
Gaylor AS and Reilly JC Therapy with macrolides in patients with cystic fibrosis. 2002 Pharmacotherapy pmid:11837560
Adelglass J et al. A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis. 1998 Nov-Dec Pharmacotherapy pmid:9855324
Kang-Birken SL and Prichard JG Mycobacterium szulgai in a patient with advanced acquired immunodeficiency syndrome: an unusual pathogen with unusual multidrug resistance. 2006 Pharmacotherapy pmid:17064210
Guerriero SE et al. Two cases of clarithromycin-induced digoxin toxicity. 1997 Sep-Oct Pharmacotherapy pmid:9324195
McConnell SA and Amsden GW Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin. 1999 Pharmacotherapy pmid:10212011
Molden E and Andersson KS Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. 2007 Pharmacotherapy pmid:17381388
Oberg KC Delayed elevation of international normalized ratio with concurrent clarithromycin and warfarin therapy. 1998 Mar-Apr Pharmacotherapy pmid:9545160
Shin J et al. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. 2011 Pharmacotherapy pmid:21950641
Stein GE et al. A preliminary study of clarithromycin versus doxycycline in the treatment of nongonococcal urethritis and mucopurulent cervicitis. 1995 Nov-Dec Pharmacotherapy pmid:8602379
Stein GE and Schooley S Serum bactericidal activity of extended-release clarithromycin against macrolide-resistant strains of Streptococcus pneumoniae. 2002 Pharmacotherapy pmid:12013358
Sketris IS et al. Possible role of the intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction. 1996 Mar-Apr Pharmacotherapy pmid:8820476
Legendre DP et al. Hansen's disease (Leprosy): current and future pharmacotherapy and treatment of disease-related immunologic reactions. 2012 Pharmacotherapy pmid:22392826
Schulz-Du Bois C et al. Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine. 2008 Pharmacopsychiatry pmid:19067264
Kitano M et al. Effects of clarithromycin and dexamethasone on mucus production in isografted rat trachea. 2011 Pharmacology pmid:21228611
Jokinen MJ et al. Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine. 2001 Pharmacol. Toxicol. pmid:11322176
Yamamoto K et al. Clarithromycin prevents human respiratory syncytial virus-induced airway epithelial responses by modulating activation of interferon regulatory factor-3. 2016 Pharmacol. Res. pmid:27468646
Calabresi L et al. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. 2004 Pharmacol. Res. pmid:14998561
Pauwels O Factors contributing to carbamazepine-macrolide interactions. 2002 Pharmacol. Res. pmid:12030792
Woo PC et al. Clarithromycin attenuates cyclophosphamide-induced mucositis in mice. 2000 Pharmacol. Res. pmid:10753551
Marjanović N et al. Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. 2011 Pharmacol. Res. pmid:21315154
Woo PC et al. Clarithromycin attenuates the inflammatory response induced by surgical trauma in a guinea pig model. 1999 Pharmacol. Res. pmid:10051377
Karczewska E et al. Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland. 2011 Pharmacol Rep pmid:21857091
Szałek E et al. Sunitinib in combination with clarithromycin or azithromycin - is there a risk of interaction or not? 2012 Pharmacol Rep pmid:23406766
Fohner AE et al. PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. 2017 Pharmacogenet. Genomics pmid:28146011
Allen LaPointe NM et al. Frequency of high-risk use of QT-prolonging medications. 2006 Pharmacoepidemiol Drug Saf pmid:16178046
Quach C et al. Effectiveness of amoxicillin, azithromycin, cefprozil and clarithromycin in the treatment of acute otitis media in children: a population-based study. 2005 Pharmacoepidemiol Drug Saf pmid:15386697
Galatti L et al. Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug-drug interactions: a four-year analysis from Italian general practice. 2007 Pharmacoepidemiol Drug Saf pmid:17323404
Corrao G et al. Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials. 2005 Pharmacoepidemiol Drug Saf pmid:15390219
Drinkard CR et al. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. 2000 Pharmacoepidemiol Drug Saf pmid:11338912
Bérard A et al. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. 2015 Pharmacoepidemiol Drug Saf pmid:26513406
Craig AM et al. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin. 1996 Pharmacoeconomics pmid:10160472
Agro K et al. Cost effectiveness in Canada of a multidrug prepackaged regimen (Hp-PAC)+ for Helicobacter pylori eradication. 2001 Pharmacoeconomics pmid:11596835
Plosker GL and Figgitt DP Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. 2004 Pharmacoeconomics pmid:15099124
Ufuk A et al. In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383. 2015 Pharm. Res. pmid:26224396
Dimer F et al. Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections. 2015 Pharm. Res. pmid:26113237
Vehring R Pharmaceutical particle engineering via spray drying. 2008 Pharm. Res. pmid:18040761
Kita T et al. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability. 2001 Pharm. Res. pmid:11465416
Haghi M et al. Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler. 2015 Pharm. Res. pmid:25537341
Lu MY et al. A polymer carrier system for taste masking of macrolide antibiotics. 1991 Pharm. Res. pmid:1829521
Rotsch TD et al. Determination of clarithromycin as a contaminant on surfaces by high-performance liquid chromatography using electrochemical detection. 1991 Pharm. Res. pmid:1833731
Meng Y et al. Multi-functional Liposomes Enhancing Target and Antibacterial Immunity for Antimicrobial and Anti-Biofilm Against Methicillin-Resistant Staphylococcus aureus. 2016 Pharm. Res. pmid:26666773
Takeuchi T et al. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. 2006 Pharm. Res. pmid:16779700
Rose WE et al. Prevention of biofilm formation by methacrylate-based copolymer films loaded with rifampin, clarithromycin, doxycycline alone or in combination. 2015 Pharm. Res. pmid:24934663
Becker ML et al. Determinants of potential drug-drug interaction associated dispensing in community pharmacies in the Netherlands. 2007 Pharm World Sci pmid:17187223
Sancar M et al. Pharmacoeconomic comparison of Helicobacter pylori eradication regimens. 2006 Pharm World Sci pmid:17066247